Cambridge Healthtech Institute Announces its Inaugural Biologics Formulation & Delivery Summit

Released on: February 24, 2014, 7:27 am (EST)
Industry: Pharmaceuticals

Needham, MA, -- /EPR NETWORK/ -- Cambridge Healthtech Institute (CHI) today announced it will host its inaugural "Biologics Formulation & Delivery Summit" -- an international forum for the pharmaceutical and device industries to identify courses of action in biotherapeutics delivery on May 5-7, 2014 at the World Seaport Trade Center in Boston, MA. This two-part summit will discuss various formulation and device-based approaches for designing physiologically relevant, patient friendly, targeted biologics products.

Part 1: Formulation Strategies for Improved Delivery of Biologics (May 5-6)

Overcoming Challenges in Injectable Drug Delivery via Breakthrough Delivery and Device Strategies is the main theme of this conference with a keynote presentation by Julia Rashba-Step, Ph.D., Senior Director, Novel Delivery Technologies, Pfizer, Inc., will educate the audience on the future trends on biotherapeutics and importance of drug delivery in commercial, clinical differentiation and also the need for enabling technologies. In addition, strategic plans for current and future delivery reflective of needs of Pfizer's biotherapeutics portfolio will be discussed.

Part 2: New Technologies for Biologics Delivery and Targeting (May 6-7)

Driving Innovation Through New Targets, Effective Tools, Next-Gen and Alternate Delivery Technologies is the main theme of this conference with a keynote presentation by Omid Farokhzad, M.D., Associate Professor, Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital and Harvard Medical School, on the design and optimization of polymeric nanoparticles for medical applications, which formed the foundation for the clinical translation of the first-in-human targeted and controlled-release nanoparticles, BIND-014 and SEL-068.

Advances in molecular biology and biotechnology have allowed for the large-scale production of effective and potent biotherapeutic drugs. Major research issues in protein/peptide delivery include the stabilization of proteins in delivery devices and the design of appropriate target-specific carriers. "This summit will be an excellent forum for focused discussions, initiate new collaborations, socialize and interact with colleagues from around the world who are facing similar challenges and utilizing compelling strategies. CHI looks forward to adding this Summit to its portfolio of scientific events scheduled for 2014," states CHI conference director, Nandini Kashyap.

The rest of the summit includes talks by MedImmune, Allergan, Shire, MannKind, Novartis, Northeastern University, Duke University, to name a few. Plus, delegates may choose from three interactive short courses geared towards turning their technologies into successful patient-friendly products. The summit is co-located with PEGS: the essential protein engineering summit where 1600+ delegates and 100+ exhibitors will be in attendance. Delegates have access to a shared exhibit hall with the PEGS attendees, joint exhibit hall reception and networking breaks.

The Summit offers student fellowship awards to full-time graduate students and Ph.D. candidates. For further information, to apply for a student fellowship, or to register, visit

To receive a press pass or arrange an interview with a speaker, email Lisa Scimemi at

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), founded in 1992, is the industry leader in providing superior quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group. For more information, visit

Contact-Details: James Prudhomme

WORD not available PDF not available PRINT not available

Back to previous page
Home page
Submit your press release